Lentinus edodes Mycelium Extract for Peripheral Sensory Neuropathy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anticancer drugs like oxaliplatin, paclitaxel, vincristine, and bortezomib cause peripheral sensory neuropathy, leading to severe side effects such as numbness, pain, and impaired motor functions, which can force the discontinuation of effective cancer treatments and significantly impact patients' quality of life, with no established effective therapy.
Innovation Solution
A composition containing Lentinus edodes mycelium extract is used to ameliorate peripheral sensory neuropathy, which can be administered orally and is effective in reducing symptoms like allodynia, hyperesthesia, and impaired motor functions when co-administered with these anticancer drugs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anticancer drugs (oxaliplatin, paclitaxel, vincristine, bortezomib) are administered to treat cancer, then cancer treatment effectiveness is improved, but peripheral sensory neuropathy symptoms (numbness, pain, allodynia, hyperesthesia) worsen
Solution Approach 1:
The patent introduces an extract from Lentinus edodes (shiitake mushroom) as an intermediary substance that mediates between the anticancer drugs and the nervous system. This extract contains specific compounds that protect peripheral nerves from drug-induced damage while allowing the anticancer drugs to maintain their therapeutic effectiveness against cancer cells.
Solution Approach 2:
The patent converts the harmful effect of anticancer drugs on peripheral nerves into a beneficial outcome by using Lentinus edodes extract to prevent nerve damage. The extract transforms the potentially harmful interaction between chemotherapy drugs and nervous tissue into a protective mechanism that preserves neurological function during cancer treatment.
2Productivity
If anticancer drugs are continued at effective doses, then cancer treatment outcomes are improved, but peripheral sensory neuropathy severity increases leading to treatment discontinuation
Solution Approach 1:
The patent applies preliminary action by administering Lentinus edodes extract before or during the initiation of anticancer drug therapy. This preventive approach protects peripheral nerves from developing neuropathy symptoms in the first place, allowing patients to continue effective doses of anticancer drugs without interruption due to neurological side effects.
3Ease of operation
If peripheral sensory neuropathy symptoms occur, then quality of life deteriorates, but reducing or discontinuing anticancer drugs improves neurological symptoms
Solution Approach 1:
The Lentinus edodes extract serves as a mediator that allows both cancer treatment effectiveness and quality of life to be maintained. By protecting peripheral nerves from drug-induced damage, the extract enables patients to continue effective anticancer therapy while experiencing fewer neurological side effects that would otherwise deteriorate their quality of life.
Data Source
AI summary
No drug has been available for treating a peripheral sensory neuropathy caused as a side effect by a drug, in particular, by an anticancer drug such as oxaliplatin.A composition for ameliorating peripheral sensory neuropathy, which is characterized by including a Lentinus edodes mycelium extract, ameliorates symptoms induced by the drug such as the anticancer drug, including numbness of extremities, a pain in extremities, a reduction in deep tendon reflection, a reduction in muscle force, allodynia, hyperalgesia, impaired finger fine movement, impaired walking, stumbling, falling, impaired flexion (being difficult or impossible to sit on one's heels, sit cross-legged, sit with one's legs out to one side, sit on a chair, or the like), or paralysis of extremities.